Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Endocrine, metabolic disorders tied to poor HRQOL, physical activity in childhood cancer survivors

03 Dec 2019

Endocrine and metabolic disorders independently predict low health-related quality of life (HRQOL) and suboptimal physical activity among childhood cancer survivors, suggests a study.

A total of 7,287 survivors (median age at last follow-up survey, 32 years; range, 18–54 years), of whom 4,884 (67 percent) reported at least one endocrine or metabolic disorder. Those with either disorder were more likely to be male, older, have received radiation therapy and have experienced other chronic health conditions.

After controlling for covariates, endocrine or metabolic disorders were associated with poor physical function (risk ratio [RR], 1.25, 95 percent confidence interval [CI], 1.05–1.48), increased bodily pain (RR, 1.27, 95 percent CI, 1.12–1.44), poor general health (RR, 1.49, 95 percent CI, 1.32–1.68) and lower vitality (RR, 1.21, 95 percent CI, 1.09–1.34).

Furthermore, survivors with growth disorders (RR, 0.90, 95 percent CI, 0.83–0.97), osteoporosis (RR, 0.87, 95 percent CI, 0.76–0.99) and overweight/obesity (RR, 0.92, 95 percent CI, 0.88–0.96) were less likely to meet the recommended physical activity.

This retrospective review with longitudinal follow-up was conducted in a cohort of childhood cancer survivors enrolled in the North American Childhood Cancer Survivor Study to determine the independent effects of endocrine and metabolic disorders on HRQOL and physical activity.

The investigators used the Medical Outcomes Short Form-36 to assess HRQOL and dichotomized participation in physical activity as meeting or not meeting recommendations from the Centers for Disease Control and Prevention. The association of each endocrine or metabolic disorder with HRQOL scales and physical activity was evaluated using log binomial regression.

“Childhood cancer survivors experience chronic health conditions that impact HRQOL and participation in optimal physical activity,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.